Sign In
Buy TRAW
$0.84
-0.0543 (-6.09%)
At Close: Jun 23, 2026
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
07:00am, Monday, 22'nd Jun 2026
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of updated data package to MHRA, expected in 3Q 2026, to e
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study
11:10am, Monday, 15'th Jun 2026
Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.
Traws Pharma Provides Regulatory Update on Influenza Program
05:30pm, Friday, 12'th Jun 2026
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats,
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
08:45am, Wednesday, 27'th May 2026
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
07:00am, Friday, 15'th May 2026
Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027
Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak
10:41am, Friday, 08'th May 2026
Traws Pharma, Inc. (NASDAQ:TRAW) shares are up during Friday's session, trading higher by 25.86% as the company is advancing potential clinical candidates for the treatment of hantavirus infections.
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
07:30am, Friday, 08'th May 2026
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel the
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
10:56am, Monday, 20'th Apr 2026
Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement a
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
12:41am, Thursday, 16'th Apr 2026
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
04:01pm, Wednesday, 15'th Apr 2026
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
Traws Pharma (NASDAQ:TRAW) Shares Up 8.8% – Should You Buy?
03:01am, Tuesday, 14'th Apr 2026
Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shot up 8.8% on Monday. The stock traded as high as $1.64 and last traded at $1.61. 21,635 shares were traded during trading, a decline of 60% from
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; re
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpil
SAN DIEGO , Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services c
DOVER, Del. , Oct. 22, 2025 /PRNewswire/ -- Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates Phase 2 c
